摘要:
The present invention provides an antenna that is small in size and has band frequencies corresponding to multibands, and a wireless communication apparatus including the antenna. The antenna according to the present invention has two radiation elements 12a and 12b connected to a ground plate 11 via a shorting pin. The two radiation elements 12a and 12b each have a lower arm and an upper arm that are formed through bending. The lower arm is connected to the shorting pin and is located closer to the ground plate 11 than the upper arm is. At least one of the lower arm and the upper arm has a meandered structure.
摘要:
The present invention relates to a novel two cyclic cinnamide compound and a pharmaceutical agent comprising the compound as an active ingredient. The two cyclic cinnamide compound represented by the general formula (I): wherein represents a single bond or a double bond; Ar1 represents a phenyl group or pyridinyl group that may be substituted with 1 to 3 substituents; R1 and R2 each represent a C1-6 alkyl group, a hydroxyl group, or the like; Z1 represents a methylene group or vinylene group, which may be substituted with 1 or 2 substituents selected from Substituent Group A1, an oxygen atom, or an imino group that may be substituted with a substituent selected from Substituent Group A1; and p, q, and r each represent an integer of 0 to 2, which has an effect of reducing Aβ40 and Aβ42 production, and thus is particularly useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ such as Alzheimer's disease or Down's syndrome.
摘要翻译:本发明涉及一种新型的两种环状肉桂酰胺化合物和包含该化合物作为活性成分的药剂。 由通式(I)表示的两个环状肉桂酰胺化合物:其中表示单键或双键; Ar 1表示可被1〜3个取代基取代的苯基或吡啶基; R1和R2各自表示C1-6烷基,羟基等; Z1表示亚甲基或亚乙烯基,其可以被1或2个选自取代基组A1,氧原子或可被选自取代基组A1的取代基取代的亚氨基取代基取代; p,q和r各自表示0〜2的整数,其具有降低A&bgr 40和A&bgr 42生成的效果,因此特别可用作由A&bgr引起的神经变性疾病的预防或治疗剂。 如阿尔茨海默病或唐氏综合症。
摘要:
The present invention relates to a compound represented by formula (I): wherein R1 represents a C1-3 alkyl group, R2 represents a hydrogen atom or a C1-3 alkyl group, Ar represents a phenyl group or the like which may be substituted with 1 to 3 substituents, X represents an oxygen atom or the like, n and m are the same or different and integers of 0 to 2, or a pharmacologically acceptable salt, and use thereof as a medicament.
摘要:
The present invention provides a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, Ar2 represents a phenyl group that may be substituted with a C1-6 alkoxy group, or the like, X1 represents a double bond or the like, and Het represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, which is effective as a therapeutic or prophylactic agent for a disease caused by Aβ.
摘要:
The present invention provides a novel compound having an excellent AMPA receptor inhibitory action and/or kainate inhibitory action. A compound represented by the following formula, a salt thereof or hydrates thereof. In the formula, Q indicates NH, O or S; and R1, R2, R3, R4 and R5 are the same as or different from each other and each indicates hydrogen atom, a halogen atom, a C1-6 alkyl group or a group represented by the formula —X-A (wherein X indicates a single bond, an optionally substituted C1-6 alkylene group etc.; and A indicates an optionally substituted C6-14 aromatic hydrocarbocyclic group or 5- to 14-membered aromatic heterocyclic group etc.).
摘要:
An amorphous object of (3E)-1-[l(s)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4methyl-1H-imidazol-1-yl)benzylidene]piperidine-2-one, which is represented by the formula (1) and has Aβ-production inhibitory activity. The amorphous object has such satisfactory properties that it has excellent solubility, is stable, does not readily become a crystalline form, and has low hygroscopicity. It is hence suitable for use in pharmaceutical preparations.
摘要:
Disclosed is a compound represented by the formula (I) below or a pharmacologically acceptable salt thereof. Also disclosed is a use of the compound or salt as a pharmaceutical product. (In the formula, Ar1 represents an imidazolyl group which may be substituted with a C1-6 alkyl group; Ar2 represents a phenyl group which may be substituted with a C1-6 alkoxy group; X1 represents a single bond; R1 and R2 respectively represent a C1-6 alkyl group or the like which may be substituted with a substituent such as a 5- to 14-membered aromatic heterocyclic group; and R3 represents a hydrogen atom or the like.)
摘要翻译:公开了由下式(I)表示的化合物或其药理学上可接受的盐。 还公开了化合物或盐作为药物产品的用途。 (式中,Ar 1表示可被C 1-6烷基取代的咪唑基,Ar 2表示可被C 1-6烷氧基取代的苯基,X 1表示单键; R 1,R 2分别表示 可以被诸如5至14元芳族杂环基团的取代基取代的C 1-6烷基等; R 3表示氢原子等。
摘要:
A system for comparing dental X-ray images includes a positional displacement calculator calculating a positional displacement between dental X-ray test and reference images by using phase-only correlation, a positional displacement corrector correcting the positional displacement, a base point extractor defining, as a base image, any one of the dental X-ray test and reference images, and defining, as a corresponding image, the other one of the two dental images, and extracting base points from the base image, a corresponding point extractor extracting corresponding points, which correspond to the base points, from the corresponding image, a correspondence calculator calculating correspondence between the base points and the corresponding points, a nonlinear distortion corrector correcting a nonlinear distortion between the base image and the corresponding image, based on the correspondence, and a similarity calculator finding, by using phase-only correlation, a similarity between the base image and the corresponding image.
摘要:
The invention provides crystals of dihydrochloride monohydrate of the compound of the following formula having an Aβ production inhibiting effect which crystals are characterized by exhibiting a diffraction peak at an angle of diffraction (2θ±0.2°) of 10.9° in powder X-ray diffractometry. Further, the invention also provides the compound in the form of various salts, crystal forms and amorphous forms which are suitable for the development of drugs.
摘要:
An ophthalmic laser treatment apparatus comprises: a laser source that emits a laser beam for treatment of an affected part of a patient's eye; an optical fiber that transmits the laser beam emitted from the laser source; and a delivery optical system that irradiates the laser beam emitted from the optical fiber to the affected part of the patient's eye, the delivery optical system including: a plurality of diffraction optical elements each being configured to shape a beam profile of the laser beam at an emission end face of the optical fiber into a beam profile having one of a uniform intensity and a lower intensity in the center than on the periphery on the affected part and also to shape the laser beam to have a different spot size on the affected part of the patient's eye; and a changing unit which selectively disposing one of the diffraction optical elements on an optical path.